66 related articles for article (PubMed ID: 11366339)
1. Death halts study.
Posit Aware; 2000; 11(1):23. PubMed ID: 11366339
[TBL] [Abstract][Full Text] [Related]
2. DOTC also goes down.
Posit Aware; 2000; 11(1):23. PubMed ID: 11366340
[TBL] [Abstract][Full Text] [Related]
3. [Approval of a new nucleoside. Component of complete once daily regimen].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
[No Abstract] [Full Text] [Related]
4. Tenofovir: FDA hearing October 3, public comment deadlines September 26.
James JS
AIDS Treat News; 2001 Aug; (370):3-4. PubMed ID: 11570163
[No Abstract] [Full Text] [Related]
5. For people needing a new drug.
Vazquez E
Posit Aware; 1999; 10(2):45-6. PubMed ID: 11366852
[TBL] [Abstract][Full Text] [Related]
6. FddA: antiretroviral in development.
Hanna L
BETA; 1998 Oct; ():7-8. PubMed ID: 11365997
[TBL] [Abstract][Full Text] [Related]
7. Nucleoside reverse-transcriptase inhibitor use, cirrhosis, and end-stage liver disease in HIV-infected patients.
Remtulla RA; Decker CF
Clin Infect Dis; 2008 Nov; 47(9):1233-4; author reply 1234. PubMed ID: 18831698
[No Abstract] [Full Text] [Related]
8. FDA notifications. NRTI Emtriva receives FDA approval.
AIDS Alert; 2003 Oct; 18(10):131-2. PubMed ID: 14686301
[TBL] [Abstract][Full Text] [Related]
9. On approval.
Huff B
GMHC Treat Issues; 2001 Oct; 15(10):5-8. PubMed ID: 11727570
[No Abstract] [Full Text] [Related]
10. Renal safety of tenofovir disoproxil fumarate.
Sax PE; Gallant JE; Klotman PE
AIDS Read; 2007 Feb; 17(2):90-2, 99-104, C3. PubMed ID: 17323508
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.
Atta MG; Fine DM
AIDS Read; 2009 Mar; 19(3):118-9. PubMed ID: 19334329
[No Abstract] [Full Text] [Related]
12. Zerit vs. Retrovir.
Posit Aware; 2000; 11(1):25. PubMed ID: 11366345
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside analogues in 2008.
Warwick Z; Churchill D
J HIV Ther; 2008 Mar; 13(1):3-8. PubMed ID: 18953267
[No Abstract] [Full Text] [Related]
14. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
[No Abstract] [Full Text] [Related]
15. Apricitabine: a nucleoside reverse transcriptase inhibitor for HIV infection.
Gaffney MM; Belliveau PP; Spooner LM
Ann Pharmacother; 2009 Oct; 43(10):1676-83. PubMed ID: 19737995
[TBL] [Abstract][Full Text] [Related]
16. FDA grants tentative approval to first generic version of antiretroviral Viread.
AIDS Patient Care STDS; 2008 Jan; 22(1):86. PubMed ID: 18453039
[No Abstract] [Full Text] [Related]
17. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
[No Abstract] [Full Text] [Related]
18. Viramune (Nevirapine) is approved for children.
Vazquez E
Posit Aware; 1998; 9(6):17. PubMed ID: 11366470
[TBL] [Abstract][Full Text] [Related]
19. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
Kakuda TN; Anderson PL; Becker SL
AIDS; 2004 Dec; 18(18):2442-4. PubMed ID: 15622326
[No Abstract] [Full Text] [Related]
20. Lodenosine trials stopped due to safety concerns.
Highleyman L
BETA; 1999; 12(4):4. PubMed ID: 11367250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
